Merck Reaches Mutual Agreement with Ono Pharmaceutical to Terminate the License Agreement on Ceralifimod

18-Jun-2014 - Germany

Merck announced that it has reached a mutual agreement with Ono Pharmaceutical Co., Ltd., Osaka, Japan, to terminate the license agreement on ceralifimod (ONO-4641) because it does not meet Merck’s threshold for continued investment. Merck obtained worldwide exclusive license rights from Ono Pharmaceutical for the development and commercialization of ceralifimod (ONO-4641) in multiple sclerosis (MS) outside of Japan, Korea and Taiwan in October 2011. The drug candidate is currently in clinical development (Phase II).

Merck Serono, the biopharmaceutical division of Merck, remains committed to improving the lives of people with MS, and will continue to pursue external collaborations and internal development programs aimed at identifying and developing high quality candidate molecules with the goal of making a real difference in the lives of people with MS.

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance